CEO Martine Rothblatt was paid $18,038,972 in fiscal year 2025, ↓ down 21.6% from fiscal year 2024, the 54th percentile of its disclosed peer group (SEC filing 0001082554-26-000009 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$18,038,972 ↓ Martine Rothblatt total, FY2025 | 54th CEO pay percentile vs peers | 76:1 CEO-to-median pay ratio | 97.05% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
UTHR's next annual pay disclosure, estimated April 29, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Martine Rothblatt | $1,545,005 | $0 | $6,067,990 | $6,075,804 | $4,281,875 | $55,898 | $12,400 | $18,038,972 |
| Chairperson and Chief Executive Officer | ||||||||
| Michael Benkowitz | 1,442,308 | 0 | 3,121,558 | 3,124,134 | 3,315,000 | 3,328,735 | 53,920 | 14,385,655 |
| President and Chief Operating Officer | ||||||||
| James Edgemond | 955,769 | 0 | 1,950,974 | 1,953,133 | 1,616,063 | 1,849,381 | 23,047 | 8,348,367 |
| Chief Financial Officer and Treasurer | ||||||||
| Paul Mahon | 964,231 | 0 | 1,517,766 | 1,519,226 | 1,500,590 | 0 | 29,500 | 5,531,313 |
| Executive Vice President and General Counsel | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Martine Rothblatt | $18,038,972 | $23,009,609 | $16,958,057 | ↓ −4,970,637 |
| Michael Benkowitz | 14,385,655 | 13,893,389 | 9,806,551 | ↑ +492,266 |
| James Edgemond | 8,348,367 | 9,164,549 | 6,054,484 | ↓ −816,182 |
| Paul Mahon | 5,531,313 | 6,963,308 | 5,153,601 | ↓ −1,431,995 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read UNITED THERAPEUTICS Corp's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper UTHR reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
Get the UNITED THERAPEUTICS Corp Peer Teardown Report
$18,038,972 Martine Rothblatt total, FY2025
$199
The free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.
Data as of October 16, 2026 · Source: 0001082554-26-000009 · Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).
Reports for UTHR
Every report below is generated from the same filings as the free brief above, at the moment of purchase. What each one adds:
Order UTHR
Pick the report, add the email the receipt and the PDF go to, and pay by card on Stripe.
How we handle your data → Privacy
Each company listed discloses UTHR in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named UTHR in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Get the UNITED THERAPEUTICS Corp Executive Compensation Report
$1,500
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Christopher Causey | Independent Director | $508,034 |
| Christopher Patusky | Lead Independent Director | $541,312 |
| Jan Malcolm | Independent Director | $470,265 |
| Judy Olian | Independent Director | $476,397 |
| Linda Maxwell | Independent Director | $489,556 |
| Louis Sullivan | Independent Director | $499,127 |
| Nilda Mesa | Independent Director | $493,743 |
| Ray Kurzweil | Independent Director | $463,743 |
| Raymond Dwek | Independent Director | $484,784 |
| Richard Giltner | Independent Director | $501,397 |
| Tommy Thompson | Independent Director | $483,034 |
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Martine Rothblatt | Director | 2026-10-01 | D | 560 | $573 | $320,803 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-01 | D | 320 | 572 | 182,888 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-01 | D | 534 | 571 | 304,673 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-01 | D | 160 | 563 | 90,130 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-01 | D | 80 | 562 | 44,934 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-01 | D | 9,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-01 | D | 360 | 585 | 210,478 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-01 | D | 400 | 583 | 233,313 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-01 | D | 702 | 581 | 408,012 | Common | Form 4 ↗ |
| Paul Mahon | EVP & GENERAL COUNSEL | 2026-10-01 | D | 160 | 573 | 91,704 | Common | Form 4 ↗ |
| Paul Mahon | EVP & GENERAL COUNSEL | 2026-10-01 | D | 838 | 571 | 478,411 | Common | Form 4 ↗ |
| Paul Mahon | EVP & GENERAL COUNSEL | 2026-10-01 | D | 400 | 566 | 226,562 | Common | Form 4 ↗ |
| Paul Mahon | EVP & GENERAL COUNSEL | 2026-10-01 | D | 1,480 | 563 | 833,374 | Common | Form 4 ↗ |
| Paul Mahon | EVP & GENERAL COUNSEL | 2026-10-01 | A | 8,300 | 146 | 1,212,049 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-01 | D | 320 | 579 | 185,286 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-01 | D | 930 | 578 | 537,477 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-01 | D | 94 | 568 | 53,383 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-01 | A | 9,500 | 118 | 1,118,720 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-01 | D | 306 | 570 | 174,314 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-01 | D | 520 | 582 | 302,765 | Common | Form 4 ↗ |
| Paul Mahon | EVP & GENERAL COUNSEL | 2026-10-01 | D | 720 | 568 | 408,788 | Common | Form 4 ↗ |
| Paul Mahon | EVP & GENERAL COUNSEL | 2026-10-01 | D | 780 | 562 | 438,259 | Common | Form 4 ↗ |
| Paul Mahon | EVP & GENERAL COUNSEL | 2026-10-01 | D | 1,480 | 560 | 829,083 | Common | Form 4 ↗ |
| Paul Mahon | EVP & GENERAL COUNSEL | 2026-10-01 | D | 880 | 558 | 491,308 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-01 | D | 774 | 577 | 446,525 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-01 | D | 120 | 560 | 67,206 | Common | Form 4 ↗ |
| Paul Mahon | EVP & GENERAL COUNSEL | 2026-10-01 | D | 8,300 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Paul Mahon | EVP & GENERAL COUNSEL | 2026-10-01 | D | 823 | 572 | 470,961 | Common | Form 4 ↗ |
| Paul Mahon | EVP & GENERAL COUNSEL | 2026-10-01 | D | 739 | 569 | 420,600 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-02 | D | 40 | 574 | 22,969 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-02 | D | 120 | 571 | 68,484 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-02 | D | 240 | 570 | 136,775 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-02 | D | 80 | 567 | 45,326 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-02 | D | 80 | 564 | 45,110 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-02 | D | 120 | 561 | 67,279 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-02 | D | 120 | 559 | 67,032 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-02 | D | 240 | 557 | 133,784 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-02 | D | 80 | 556 | 44,448 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-02 | D | 80 | 554 | 44,344 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-02 | D | 725 | 552 | 400,067 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-02 | D | 432 | 551 | 238,027 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-02 | D | 757 | 550 | 416,040 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-02 | D | 1,171 | 548 | 641,699 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-02 | D | 309 | 547 | 168,945 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-02 | D | 1,280 | 545 | 697,471 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-02 | D | 408 | 543 | 221,492 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-02 | D | 700 | 542 | 379,443 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-02 | A | 9,500 | 118 | 1,118,720 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-02 | D | 1,032 | 544 | 561,589 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-02 | D | 160 | 553 | 88,457 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-02 | D | 80 | 572 | 45,795 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-02 | D | 40 | 562 | 22,494 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-02 | D | 1,206 | 549 | 661,943 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-02 | D | 9,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-05 | D | 9,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-05 | D | 360 | 547 | 196,788 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-05 | D | 1,260 | 545 | 686,187 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-05 | D | 783 | 544 | 425,593 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-05 | D | 918 | 543 | 498,067 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-05 | D | 1,239 | 542 | 671,120 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-05 | D | 1,028 | 540 | 555,633 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-05 | D | 931 | 540 | 502,279 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-05 | D | 655 | 539 | 352,795 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-05 | D | 905 | 537 | 486,373 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-05 | D | 501 | 536 | 268,665 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-05 | D | 920 | 546 | 502,037 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-05 | A | 9,500 | 118 | 1,118,720 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-06 | D | 9,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-06 | D | 80 | 545 | 43,640 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-06 | D | 842 | 545 | 458,681 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-06 | D | 558 | 544 | 303,548 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-06 | D | 380 | 542 | 205,791 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-06 | D | 2,054 | 541 | 1,110,553 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-06 | D | 1,606 | 540 | 866,718 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-06 | D | 1,088 | 539 | 586,006 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-06 | D | 133 | 538 | 71,498 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-06 | D | 734 | 536 | 393,210 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-06 | D | 167 | 534 | 89,228 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-06 | D | 360 | 529 | 190,339 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-06 | D | 280 | 528 | 147,813 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-06 | D | 323 | 536 | 173,209 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-06 | D | 215 | 533 | 114,626 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-06 | D | 320 | 532 | 170,220 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-06 | D | 240 | 530 | 127,232 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-06 | D | 120 | 542 | 65,099 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-06 | A | 9,500 | 118 | 1,118,720 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-07 | D | 9,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-07 | D | 400 | 556 | 222,594 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-07 | D | 485 | 555 | 268,939 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-07 | D | 185 | 554 | 102,435 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-07 | D | 440 | 552 | 243,010 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-07 | D | 486 | 551 | 267,832 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-07 | D | 387 | 548 | 212,145 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-07 | D | 629 | 547 | 344,028 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-07 | D | 2,098 | 545 | 1,143,035 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-07 | D | 744 | 544 | 404,557 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-07 | D | 176 | 543 | 95,521 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-07 | D | 874 | 550 | 480,819 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-07 | D | 493 | 546 | 269,104 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-07 | D | 1,173 | 549 | 644,130 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-07 | D | 930 | 556 | 516,869 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-07 | A | 9,500 | 118 | 1,118,720 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-08 | D | 9,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-08 | D | 424 | 541 | 229,175 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-08 | D | 1,091 | 540 | 588,682 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-08 | D | 1,016 | 538 | 546,134 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-08 | D | 824 | 537 | 442,165 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-08 | D | 480 | 535 | 257,020 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-08 | D | 920 | 534 | 491,539 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-08 | D | 800 | 533 | 426,689 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-08 | D | 600 | 532 | 319,244 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-08 | D | 1,061 | 531 | 563,468 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-08 | D | 199 | 530 | 105,497 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-08 | D | 200 | 529 | 105,725 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-08 | D | 273 | 528 | 144,028 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-08 | D | 767 | 527 | 403,951 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-08 | D | 200 | 525 | 105,099 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-08 | A | 9,500 | 118 | 1,118,720 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-08 | D | 40 | 541 | 21,649 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-08 | D | 605 | 539 | 325,853 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-09 | D | 9,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-09 | D | 423 | 551 | 232,954 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-09 | D | 1,478 | 550 | 812,796 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-09 | D | 878 | 548 | 481,155 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-09 | D | 240 | 547 | 131,184 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-09 | D | 400 | 546 | 218,360 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-09 | D | 400 | 545 | 217,818 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-09 | D | 240 | 543 | 130,371 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-09 | D | 40 | 542 | 21,660 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-09 | D | 200 | 539 | 107,846 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-09 | D | 360 | 537 | 193,337 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-09 | D | 400 | 536 | 214,436 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-09 | D | 320 | 534 | 170,816 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-09 | D | 120 | 532 | 63,830 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-09 | A | 9,500 | 118 | 1,118,720 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-09 | D | 2,641 | 549 | 1,449,736 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-09 | D | 320 | 541 | 173,037 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-09 | D | 400 | 538 | 215,330 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-09 | D | 640 | 535 | 342,270 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-12 | D | 135 | 554 | 74,852 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-12 | D | 558 | 553 | 308,535 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-12 | D | 1,857 | 552 | 1,024,920 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-12 | D | 2,628 | 551 | 1,448,297 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-12 | D | 2,565 | 550 | 1,410,825 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-12 | D | 1,329 | 549 | 729,639 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-12 | D | 428 | 548 | 234,599 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-12 | A | 9,500 | 118 | 1,118,720 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-12 | D | 9,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-13 | D | 9,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-13 | D | 80 | 551 | 44,119 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-13 | D | 160 | 551 | 88,095 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-13 | D | 502 | 549 | 275,833 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-13 | D | 698 | 548 | 382,844 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-13 | D | 630 | 547 | 344,908 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-13 | D | 1,452 | 546 | 793,459 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-13 | D | 1,507 | 546 | 822,102 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-13 | D | 2,340 | 543 | 1,271,750 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-13 | D | 639 | 543 | 346,822 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-13 | A | 9,500 | 118 | 1,118,720 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-13 | D | 1,492 | 545 | 812,483 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-14 | D | 9,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-14 | D | 40 | 546 | 21,840 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-14 | D | 480 | 545 | 261,830 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-14 | D | 480 | 544 | 261,289 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-14 | D | 400 | 543 | 217,262 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-14 | D | 883 | 542 | 478,644 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-14 | D | 1,930 | 541 | 1,044,509 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-14 | D | 2,002 | 540 | 1,081,544 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-14 | D | 525 | 539 | 283,023 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-14 | D | 1,127 | 538 | 606,326 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-14 | D | 633 | 537 | 340,039 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-14 | D | 400 | 536 | 214,356 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-14 | D | 240 | 535 | 128,312 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-14 | D | 40 | 532 | 21,299 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-14 | D | 120 | 531 | 63,742 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-14 | D | 160 | 530 | 84,814 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-14 | D | 40 | 526 | 21,043 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-14 | A | 9,500 | 118 | 1,118,720 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-15 | D | 120 | 552 | 66,180 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-15 | D | 200 | 551 | 110,143 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-15 | D | 1,009 | 550 | 554,704 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-15 | D | 2,039 | 549 | 1,119,183 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-15 | D | 2,166 | 548 | 1,186,593 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-15 | D | 601 | 547 | 328,713 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-15 | D | 825 | 546 | 450,347 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-15 | D | 269 | 545 | 146,539 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-15 | D | 371 | 543 | 201,599 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-15 | D | 456 | 543 | 247,462 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-15 | D | 1,163 | 542 | 629,864 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-15 | D | 281 | 540 | 151,874 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-15 | A | 9,500 | 118 | 1,118,720 | Common | Form 4 ↗ |
| Paul Mahon | EVP & GENERAL COUNSEL | 2026-10-15 | D | 8,300 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Paul Mahon | EVP & GENERAL COUNSEL | 2026-10-15 | D | 719 | 547 | 392,977 | Common | Form 4 ↗ |
| Paul Mahon | EVP & GENERAL COUNSEL | 2026-10-15 | D | 2,615 | 546 | 1,426,972 | Common | Form 4 ↗ |
| Paul Mahon | EVP & GENERAL COUNSEL | 2026-10-15 | D | 791 | 545 | 430,975 | Common | Form 4 ↗ |
| Paul Mahon | EVP & GENERAL COUNSEL | 2026-10-15 | D | 1,983 | 544 | 1,077,871 | Common | Form 4 ↗ |
| Paul Mahon | EVP & GENERAL COUNSEL | 2026-10-15 | D | 1,924 | 542 | 1,043,753 | Common | Form 4 ↗ |
| Paul Mahon | EVP & GENERAL COUNSEL | 2026-10-15 | D | 268 | 542 | 145,160 | Common | Form 4 ↗ |
| Paul Mahon | EVP & GENERAL COUNSEL | 2026-10-15 | A | 8,300 | 146 | 1,212,049 | Common | Form 4 ↗ |
| Martine Rothblatt | Director | 2026-10-15 | D | 9,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Michael Benkowitz | PSU | 2025-03-14 | 14,220 | 28,440 | — | 85,320 | $3,124,134 |
| Martine Rothblatt | PSU | 2025-03-14 | 27,655 | 55,310 | — | 165,930 | 6,075,804 |
| Paul Mahon | PSU | 2025-03-14 | 1,235 | 2,470 | — | 7,410 | 758,883 |
| Michael Benkowitz | PSU | 2025-03-14 | 2,540 | 5,080 | — | 15,240 | 1,560,779 |
| James Edgemond | PSU | 2025-03-14 | 8,890 | 17,780 | — | 53,340 | 1,953,133 |
| Paul Mahon | PSU | 2025-03-14 | 6,915 | 13,830 | — | 41,490 | 1,519,226 |
| James Edgemond | PSU | 2025-03-14 | 1,588 | 3,175 | — | 9,525 | 975,487 |
| Martine Rothblatt | PSU | 2025-03-14 | 4,938 | 9,875 | — | 29,625 | 3,033,995 |
| Paul Mahon | PSU | 2025-03-14 | 1,235 | 2,470 | — | 7,410 | 758,883 |
| James Edgemond | PSU | 2025-03-14 | 1,588 | 3,175 | — | 9,525 | 975,487 |
| Martine Rothblatt | PSU | 2025-03-14 | 4,938 | 9,875 | — | 29,625 | 3,033,995 |
| Michael Benkowitz | PSU | 2025-03-14 | 2,540 | 5,080 | — | 15,240 | 1,560,779 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Michael Benkowitz | $0 | $6,245,692 | $0 | 100.0% |
| Martine Rothblatt | 0 | 12,143,794 | 0 | 100.0% |
| Paul Mahon | 0 | 3,036,992 | 0 | 100.0% |
| James Edgemond | 0 | 3,904,107 | 0 | 100.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| James Edgemond | RSU | 10,380 | — | $5,057,655 |
| Martine Rothblatt | RSU | 48,315 | — | 23,541,484 |
| Martine Rothblatt | RSU | 37,080 | — | 18,067,230 |
| Michael Benkowitz | RSU | 15,592 | — | 7,597,202 |
| Martine Rothblatt | RSU | 32,499 | — | 15,835,138 |
| Martine Rothblatt | RSU | 29,625 | — | 14,434,781 |
| Michael Benkowitz | RSU | 24,840 | — | 12,103,290 |
| Michael Benkowitz | RSU | 17,790 | — | 8,668,178 |
| James Edgemond | RSU | 15,525 | — | 7,564,556 |
| Michael Benkowitz | RSU | 15,240 | — | 7,425,690 |
| Paul Mahon | RSU | 12,075 | — | 5,883,544 |
| James Edgemond | RSU | 9,525 | — | 4,641,056 |
| James Edgemond | Option | 58,170 | 217.5 | — |
| James Edgemond | RSU | 9,098 | — | 4,433,001 |
| Paul Mahon | RSU | 8,895 | — | 4,334,089 |
| Paul Mahon | RSU | 7,796 | — | 3,798,601 |
| Paul Mahon | RSU | 7,410 | — | 3,610,523 |
| Martine Rothblatt | Option | 207,720 | 217.5 | — |
| Michael Benkowitz | Option | 99,720 | 217.5 | — |
| Paul Mahon | Option | 49,860 | 217.5 | — |
Our executive compensation program is designed to retain and motivate our executive team, while achieving four critical objectives: pay-for-performance (with at-risk pay representing approximately 91.1% of overall Chief Executive Officer pay and approximately 83.6% of our other NEOs’ pay); incentivize alignment with shareholder interests based on delivering operating performance and stock appreciation; balancing incentives over the short-term and long-term; and market competitiveness.
| CEO STI target (% of salary) | 125% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-26 | 35,152,059 | 1,048,505 | 18,313 | 97.05% | Passed |
| 2025 | 2025-06-26 | 38,413,776 | 1,763,712 | 29,225 | 95.54% | Passed |
| 2024 | 2024-06-26 | 35,662,995 | 1,974,530 | 49,327 | 94.63% | Passed |
| 2023 | 2023-06-26 | 38,688,651 | 1,188,503 | 220,611 | 96.49% | Passed |
| 2022 | 2022-06-27 | 38,935,752 | 690,791 | 81,705 | 98.05% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-26 | 97.05%a |
| 2025 | 2025-06-26 | 95.54%b |
| 2024 | 2024-06-26 | 94.63%c |
a. Approved under the standard stated in the filing — “Abstentions have the same effect as an "against" vote.”.
b. Approved under the standard stated in the filing — “Abstentions have the same effect as an "against" vote.”.
c. Approved under the standard stated in the filing — “Abstentions have the same effect as a "against" vote.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 76 : 1 |
|---|---|
| CEO total compensation | $18,038,972 |
| Median employee compensation | $237,406 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Christopher PatuskyIndependent · Lead Independent Director · Compensation (Chair) · Nominating/Governance | $137,569 | $199,167 | $204,576 | $0 | $0 | $541,312 |
| Christopher CauseyIndependent · Nominating/Governance (Chair) · Audit | 100,000 | 0 | 408,034 | 0 | 0 | 508,034 |
| Richard GiltnerIndependent · Audit (Chair) · Nominating/Governance | 100,000 | 401,397 | 0 | 0 | 0 | 501,397 |
| Louis SullivanIndependent · Compensation | 83,478 | 199,167 | 204,576 | 0 | 11,906 | 499,127 |
| Nilda MesaIndependent · Compensation · Nominating/Governance | 90,000 | 199,167 | 204,576 | 0 | 0 | 493,743 |
| Linda MaxwellIndependent · Compensation · Nominating/Governance | 81,522 | 0 | 408,034 | 0 | 0 | 489,556 |
| Raymond DwekIndependent · Compensation · Not standing for re-election | 75,000 | 0 | 408,034 | 0 | 1,750 | 484,784 |
| Tommy ThompsonIndependent · Audit | 75,000 | 0 | 408,034 | 0 | 0 | 483,034 |
| Judy OlianIndependent · Audit | 75,000 | 401,397 | 0 | 0 | 0 | 476,397 |
| Jan MalcolmIndependent · Audit | 66,522 | 199,167 | 204,576 | 0 | 0 | 470,265 |
| Ray KurzweilIndependent | 60,000 | 199,167 | 204,576 | 0 | 0 | 463,743 |
| Martine RothblattEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $60,000 |
|---|---|
| Annual equity retainer | $400,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | — |
| Stock ownership guideline | $5,000 |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $944,091 |
| Equity awards (grant-date value) | $1,798,629 |
| All other compensation | $13,656 |
| Total cost of the board | $2,756,376 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies UNITED THERAPEUTICS Corp names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including UNITED THERAPEUTICS Corp.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Exelixis | 2025 | Michael Morrissey | $1,306,040 | $30,539,552 | $0 | $1,382,591 | $33,239,183 |
| 2 | Incyte | 2025 | William Meury | 647,260 | 27,509,657 | 2,573,998 | 1,300,000 | 32,085,952 |
| 3 | Gilead Sciences | 2025 | Daniel O'Day | 1,795,192 | 15,238,402 | 4,500,060 | 4,848,120 | 28,437,198 |
| 4 | Amgen | 2025 | Robert Bradway | 1,925,409 | 12,599,589 | 5,399,996 | 3,907,000 | 24,693,120 |
| 5 | Biogen | 2025 | Christopher Viehbacher | 1,727,885 | 18,368,875 | 0 | 3,190,875 | 23,646,004 |
| 6 | PTC Therapeutics | 2025 | Matthew Klein | 958,500 | 16,593,800 | 4,399,760 | 1,294,000 | 23,266,326 |
| 7 | Halozyme Therapeutics | 2025 | Helen Torley | 1,000,000 | 19,350,145 | 1,650,014 | 1,147,500 | 23,166,223 |
| 8 | BioMarin Pharmaceuticals | 2025 | Alexander Hardy | 1,130,769 | 16,833,629 | 1,909,310 | 1,644,500 | 21,927,563 |
| 9 | Vertex Pharmaceuticals | 2025 | Reshma Kewalramani | 1,600,000 | 15,002,270 | 0 | 4,118,640 | 21,144,261 |
| 10 | Moderna | 2025 | Stéphane Bancel | 1,677,739 | 6,897,455 | 6,897,425 | 4,302,360 | 19,932,217 |
| 11 | Jazz Pharmaceuticals | 2025 | Renee Gala | 1,003,269 | 16,138,433 | 0 | 1,980,000 | 19,151,558 |
| 12 | UNITED THERAPEUTICS Corp | 2025 | Martine Rothblatt | 1,545,005 | 6,067,990 | 6,075,804 | 4,281,875 | 18,038,972 |
| 13 | Viatris | 2025 | Scott Smith | 1,448,654 | 10,150,013 | 0 | 2,973,660 | 15,273,331 |
| 14 | Alnylam Pharmaceuticals | 2025 | Yvonne Greenstreet | 1,404,200 | 5,512,500 | 4,363,380 | 3,562,500 | 14,867,600 |
| 15 | Neurocrine Biosciences | 2025 | Kyle Gano | 920,000 | 5,750,023 | 5,750,006 | 0 | 13,448,935 |
| 16 | Ionis Pharmaceuticals | 2025 | Brett Monia | 1,051,776 | 8,444,838 | 1,438,105 | 0 | 13,350,777 |
| 17 | Pacira BioSciences | 2025 | Frank Lee | 935,308 | 9,215,500 | 0 | 738,810 | 11,636,917 |
| 18 | Illumina | 2025 | Jacob Thaysen | 1,000,000 | 8,763,122 | 0 | 1,155,000 | 11,018,895 |
| 19 | Novavax | 2025 | John Jacobs | 792,917 | 3,545,435 | 3,763,292 | 640,331 | 8,856,015 |
| 20 | Amphastar Pharmaceuticals | 2025 | Jack Yongfeng Zhang | 950,911 | 3,301,981 | 3,302,024 | 361,000 | 8,309,350 |
| 21 | ACADIA Pharmaceuticals | 2025 | Catherine Owen Adams | 930,000 | 3,240,558 | 3,234,797 | 818,559 | 8,256,518 |
| 22 | Alkermes | 2025 | Richard Pops | 1,250,769 | 0 | 5,020,812 | 1,626,000 | 7,915,081 |
| 23 | Sarepta Therapeutics | 2025 | Douglas Ingram | 1,171,425 | 6,000,005 | 0 | 649,000 | 7,840,666 |
| 24 | Regeneron Pharmaceuticals | 2025 | Leonard Schleifer | 1,979,922 | 0 | 0 | 3,682,655 | 7,280,549 |
| 25 | Myriad Genetics | 2025 | Samraat Raha | 856,901 | 3,989,729 | 0 | 814,660 | 5,686,740 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| UNITED THERAPEUTICS Corp | 221% | PSO 50 · PSU 50 | No | Aon |
| ACADIA Pharmaceuticals | 110% | Options 50 · PSU 25 · RSU 25 | Yes | Frederic W. Cook & Co., Inc. (FW Cook) |
| Alkermes | 130% | PRSU 53 · RSU 24 · Option 23 | Yes — Relative Total Shareholder Return (TSR) | Alpine Rewards LLC |
| Alnylam Pharmaceuticals | 200% | PSU 50 · RSU 25 · Option 25 | No | Pay Governance |
| Amgen | 136.0% | PSU 50 · Options 30 · RSU 20 | Yes — relative TSR | Frederic W. Cook & Co., Inc. (FW Cook) |
| Amphastar Pharmaceuticals | not disclosed | Options 50 · RSU 50 | not disclosed | Willis Towers Watson (WTW) |
| Biogen | 127% | PSU 60 · RSU 40 | Yes | Pay Governance |
| BioMarin Pharmaceuticals | 130% | PSU 66 · RSU 21 · Options 13 | Yes — Relative TSR | Aon Human Capital Solutions |
| Exelixis | 105% | PSU 50 · RSU 50 | Yes — 2025 Relative TSR Goal | Aon |
| Gilead Sciences | 180% | PSU 50 · Options 25 · RSU 25 | Yes — Relative TSR | FW Cook |
| Halozyme Therapeutics | 127.5% | PSU 50 · RSU 35 · Option 15 | No | F.W. Cook & Co., Inc. |
| Illumina | 1155% | not disclosed | Yes — 3-year rTSR performance against select companies in the Nasdaq Biotechnology Index | Aon (Aon's Human Capital Practice, a division of Aon, plc) |
| Incyte | 138.6% | Performance Shares 60 · RSU 40 | Yes — relative total shareholder return (TSR) | Aon |
| Ionis Pharmaceuticals | not disclosed | PRSU 40 · Option 30 · RSU 30 | Yes — Relative TSR | Aon |
| Jazz Pharmaceuticals | 150% | PSU 50 · RSU 50 | Yes — Relative TSR | Aon |
| Moderna | 170% | PSU 50 · Options 50 | No | Pay Governance LLC |
| Myriad Genetics | 89% | RSU 50 · PSU 50 | Yes | Mercer, LLC |
| Neurocrine Biosciences | 105% | Options 50 · PSU 30 · RSU 20 | No | Frederic W. Cook & Co., Inc. |
| Novavax | 95% | Options 50 · RSU 50 | not disclosed | Pearl Meyer |
| Pacira BioSciences | 90% | RSU 80 · PSU 20 | No | Aon |
| PTC Therapeutics | not disclosed | Option 50 · RSU 50 | Yes — TSR relative to Nasdaq Biotechnology Index | Frederic W. Cook & Co., Inc. |
| Regeneron Pharmaceuticals | 155% | Options 60 · RSU 40 | not disclosed | Pay Governance LLC |
| Sarepta Therapeutics | 100% | PSU 50 · Option 25 · RSU 25 | No | FW Cook |
| Vertex Pharmaceuticals | not disclosed | PSU 55 · RSU 45 | No | not disclosed |
| Viatris | 136.72% | PSU 65 · RSU 35 | No | Meridian Compensation Partners, LLC |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Martine Rothblatt | DEF 14A | 2026-04-29 | 0001082554-26-000009 | Section “Summary Compensation Table” · page 50. As printed: 18,038,972. Filing ↗machine: span 1993726–1993736 |
| 2 | Section 01, Michael Benkowitz | DEF 14A | 2026-04-29 | 0001082554-26-000009 | Section “Summary Compensation Table” · page 50. As printed: 14,385,655. Filing ↗machine: r8 · c9 · span 2031448–2031458 |
| 3 | Section 01, James Edgemond | DEF 14A | 2026-04-29 | 0001082554-26-000009 | Section “Summary Compensation Table” · page 50. As printed: 8,348,367. Filing ↗machine: r5 · c9 · span 2012964–2012973 |
| 4 | Section 01, Paul Mahon | DEF 14A | 2026-04-29 | 0001082554-26-000009 | Section “Summary Compensation Table” · page 50. As printed: 5,531,313. Filing ↗machine: r11 · c9 · span 2049879–2049888 |
| 5 | Section 03, Michael Benkowitz PSU | DEF 14A | 1900-01-01 | 0001082554-26-000009 | Section “Grants of Plan-Based Awards in” · grants of plan-based awards table. Filing ↗machine: span 2186148–2186157 |
| 6 | Section 03, Martine Rothblatt PSU | DEF 14A | 1900-01-01 | 0001082554-26-000009 | Section “Grants of Plan-Based Awards in” · grants of plan-based awards table. Filing ↗machine: span 2146795–2146804 |
| 7 | Section 03, Paul Mahon PSU | DEF 14A | 1900-01-01 | 0001082554-26-000009 | Section “Grants of Plan-Based Awards in” · grants of plan-based awards table. Filing ↗machine: span 2210262–2210269 |
| 8 | Section 03, Michael Benkowitz PSU | DEF 14A | 1900-01-01 | 0001082554-26-000009 | Section “Grants of Plan-Based Awards in” · grants of plan-based awards table. Filing ↗machine: span 2190876–2190885 |
| 9 | Section 03, James Edgemond PSU | DEF 14A | 1900-01-01 | 0001082554-26-000009 | Section “Grants of Plan-Based Awards in” · grants of plan-based awards table. Filing ↗machine: span 2166461–2166470 |
| 10 | Section 03, Paul Mahon PSU | DEF 14A | 1900-01-01 | 0001082554-26-000009 | Section “Grants of Plan-Based Awards in” · grants of plan-based awards table. Filing ↗machine: span 2205536–2205545 |
| 11 | Section 03, James Edgemond PSU | DEF 14A | 1900-01-01 | 0001082554-26-000009 | Section “Grants of Plan-Based Awards in” · grants of plan-based awards table. Filing ↗machine: span 2171187–2171194 |
| 12 | Section 03, Martine Rothblatt PSU | DEF 14A | 1900-01-01 | 0001082554-26-000009 | Section “Grants of Plan-Based Awards in” · grants of plan-based awards table. Filing ↗machine: span 2151517–2151526 |
| 13 | Section 03, Paul Mahon PSU | DEF 14A | 1900-01-01 | 0001082554-26-000009 | Section “Grants of Plan-Based Awards in” · grants of plan-based awards table. Filing ↗machine: span 2214980–2214987 |
| 14 | Section 03, James Edgemond PSU | DEF 14A | 1900-01-01 | 0001082554-26-000009 | Section “Grants of Plan-Based Awards in” · grants of plan-based awards table. Filing ↗machine: span 2175905–2175912 |
| 15 | Section 03, Martine Rothblatt PSU | DEF 14A | 1900-01-01 | 0001082554-26-000009 | Section “Grants of Plan-Based Awards in” · grants of plan-based awards table. Filing ↗machine: span 2156233–2156242 |
| 16 | Section 03, Michael Benkowitz PSU | DEF 14A | 1900-01-01 | 0001082554-26-000009 | Section “Grants of Plan-Based Awards in” · grants of plan-based awards table. Filing ↗machine: span 2195598–2195607 |
| 17 | Section 07, pay ratio | DEF 14A | 2026-04-29 | 0001082554-26-000009 | Section “CEO Pay Ratio”. As printed: 76 : 1. Filing ↗ |
| 18 | Section 08, Christopher Patusky | DEF 14A | 2026-04-29 | 0001082554-26-000009 | Section “Director Compensation”. As printed: 541,312. Filing ↗machine: span 1241075–1241667 |
| 19 | Section 08, Christopher Causey | DEF 14A | 2026-04-29 | 0001082554-26-000009 | Section “Director Compensation”. As printed: 508,034. Filing ↗machine: span 1204302–1204893 |
| 20 | Section 08, Richard Giltner | DEF 14A | 2026-04-29 | 0001082554-26-000009 | Section “Director Compensation”. As printed: 501,397. Filing ↗machine: span 1213675–1214268 |
| 21 | Section 08, Louis Sullivan | DEF 14A | 2026-04-29 | 0001082554-26-000009 | Section “Director Compensation”. As printed: 499,127. Filing ↗machine: span 1245560–1246155 |
| 22 | Section 08, Nilda Mesa | DEF 14A | 2026-04-29 | 0001082554-26-000009 | Section “Director Compensation”. As printed: 493,743. Filing ↗machine: span 1231931–1232525 |
| 23 | Section 08, Linda Maxwell | DEF 14A | 2026-04-29 | 0001082554-26-000009 | Section “Director Compensation”. As printed: 489,556. Filing ↗machine: span 1227368–1227963 |
| 24 | Section 08, Raymond Dwek | DEF 14A | 2026-04-29 | 0001082554-26-000009 | Section “Director Compensation”. As printed: 484,784. Filing ↗machine: span 1209098–1209692 |
| 25 | Section 08, Tommy Thompson | DEF 14A | 2026-04-29 | 0001082554-26-000009 | Section “Director Compensation”. As printed: 483,034. Filing ↗machine: span 1250124–1250718 |
| 26 | Section 08, Judy Olian | DEF 14A | 2026-04-29 | 0001082554-26-000009 | Section “Director Compensation”. As printed: 476,397. Filing ↗machine: span 1236513–1237108 |
| 27 | Section 08, Jan Malcolm | DEF 14A | 2026-04-29 | 0001082554-26-000009 | Section “Director Compensation”. As printed: 470,265. Filing ↗machine: span 1222786–1223377 |
| 28 | Section 08, Ray Kurzweil | DEF 14A | 2026-04-29 | 0001082554-26-000009 | Section “Director Compensation”. As printed: 463,743. Filing ↗machine: span 1218238–1218832 |
| 29 | Section 08, Martine Rothblatt | DEF 14A | 2026-04-29 | 0001082554-26-000009 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 30 | Section 02, Martine Rothblatt 2026-10-01 | Form 4 | 2026-10-02 | 0001106578-26-000155 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Martine Rothblatt 2026-10-01 | Form 4 | 2026-10-02 | 0001106578-26-000155 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Martine Rothblatt 2026-10-01 | Form 4 | 2026-10-02 | 0001106578-26-000155 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, Martine Rothblatt 2026-10-01 | Form 4 | 2026-10-02 | 0001106578-26-000155 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Martine Rothblatt 2026-10-01 | Form 4 | 2026-10-02 | 0001106578-26-000155 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Martine Rothblatt 2026-10-01 | Form 4 | 2026-10-02 | 0001106578-26-000155 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Martine Rothblatt 2026-10-01 | Form 4 | 2026-10-02 | 0001106578-26-000155 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Martine Rothblatt 2026-10-01 | Form 4 | 2026-10-02 | 0001106578-26-000155 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Martine Rothblatt 2026-10-01 | Form 4 | 2026-10-02 | 0001106578-26-000155 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Paul Mahon 2026-10-01 | Form 4 | 2026-10-01 | 0001231589-26-000021 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Paul Mahon 2026-10-01 | Form 4 | 2026-10-01 | 0001231589-26-000021 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Paul Mahon 2026-10-01 | Form 4 | 2026-10-01 | 0001231589-26-000021 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Paul Mahon 2026-10-01 | Form 4 | 2026-10-01 | 0001231589-26-000021 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Paul Mahon 2026-10-01 | Form 4 | 2026-10-01 | 0001231589-26-000021 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Martine Rothblatt 2026-10-01 | Form 4 | 2026-10-02 | 0001106578-26-000155 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Martine Rothblatt 2026-10-01 | Form 4 | 2026-10-02 | 0001106578-26-000155 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Martine Rothblatt 2026-10-01 | Form 4 | 2026-10-02 | 0001106578-26-000155 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Martine Rothblatt 2026-10-01 | Form 4 | 2026-10-02 | 0001106578-26-000155 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Martine Rothblatt 2026-10-01 | Form 4 | 2026-10-02 | 0001106578-26-000155 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Martine Rothblatt 2026-10-01 | Form 4 | 2026-10-02 | 0001106578-26-000155 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Paul Mahon 2026-10-01 | Form 4 | 2026-10-01 | 0001231589-26-000021 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Paul Mahon 2026-10-01 | Form 4 | 2026-10-01 | 0001231589-26-000021 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Paul Mahon 2026-10-01 | Form 4 | 2026-10-01 | 0001231589-26-000021 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Paul Mahon 2026-10-01 | Form 4 | 2026-10-01 | 0001231589-26-000021 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Martine Rothblatt 2026-10-01 | Form 4 | 2026-10-02 | 0001106578-26-000155 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, Martine Rothblatt 2026-10-01 | Form 4 | 2026-10-02 | 0001106578-26-000155 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, Paul Mahon 2026-10-01 | Form 4 | 2026-10-01 | 0001231589-26-000021 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, Paul Mahon 2026-10-01 | Form 4 | 2026-10-01 | 0001231589-26-000021 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, Paul Mahon 2026-10-01 | Form 4 | 2026-10-01 | 0001231589-26-000021 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, Martine Rothblatt 2026-10-02 | Form 4 | 2026-10-05 | 0001106578-26-000156 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, Martine Rothblatt 2026-10-02 | Form 4 | 2026-10-05 | 0001106578-26-000156 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 02, Martine Rothblatt 2026-10-02 | Form 4 | 2026-10-05 | 0001106578-26-000156 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 62 | Section 02, Martine Rothblatt 2026-10-02 | Form 4 | 2026-10-05 | 0001106578-26-000156 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 63 | Section 02, Martine Rothblatt 2026-10-02 | Form 4 | 2026-10-05 | 0001106578-26-000156 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 64 | Section 02, Martine Rothblatt 2026-10-02 | Form 4 | 2026-10-05 | 0001106578-26-000156 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 65 | Section 02, Martine Rothblatt 2026-10-02 | Form 4 | 2026-10-05 | 0001106578-26-000156 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 66 | Section 02, Martine Rothblatt 2026-10-02 | Form 4 | 2026-10-05 | 0001106578-26-000156 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 67 | Section 02, Martine Rothblatt 2026-10-02 | Form 4 | 2026-10-05 | 0001106578-26-000156 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 68 | Section 02, Martine Rothblatt 2026-10-02 | Form 4 | 2026-10-05 | 0001106578-26-000156 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 69 | Section 02, Martine Rothblatt 2026-10-02 | Form 4 | 2026-10-05 | 0001106578-26-000156 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 70 | Section 02, Martine Rothblatt 2026-10-02 | Form 4 | 2026-10-05 | 0001106578-26-000156 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 71 | Section 02, Martine Rothblatt 2026-10-02 | Form 4 | 2026-10-05 | 0001106578-26-000156 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 72 | Section 02, Martine Rothblatt 2026-10-02 | Form 4 | 2026-10-05 | 0001106578-26-000156 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 73 | Section 02, Martine Rothblatt 2026-10-02 | Form 4 | 2026-10-05 | 0001106578-26-000156 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 74 | Section 02, Martine Rothblatt 2026-10-02 | Form 4 | 2026-10-05 | 0001106578-26-000156 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 75 | Section 02, Martine Rothblatt 2026-10-02 | Form 4 | 2026-10-05 | 0001106578-26-000156 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 76 | Section 02, Martine Rothblatt 2026-10-02 | Form 4 | 2026-10-05 | 0001106578-26-000156 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 77 | Section 02, Martine Rothblatt 2026-10-02 | Form 4 | 2026-10-05 | 0001106578-26-000156 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 78 | Section 02, Martine Rothblatt 2026-10-02 | Form 4 | 2026-10-05 | 0001106578-26-000156 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 79 | Section 02, Martine Rothblatt 2026-10-02 | Form 4 | 2026-10-05 | 0001106578-26-000156 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 80 | Section 02, Martine Rothblatt 2026-10-02 | Form 4 | 2026-10-05 | 0001106578-26-000156 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 81 | Section 02, Martine Rothblatt 2026-10-02 | Form 4 | 2026-10-05 | 0001106578-26-000156 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 82 | Section 02, Martine Rothblatt 2026-10-02 | Form 4 | 2026-10-05 | 0001106578-26-000156 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 83 | Section 02, Martine Rothblatt 2026-10-02 | Form 4 | 2026-10-05 | 0001106578-26-000156 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 84 | Section 02, Martine Rothblatt 2026-10-05 | Form 4 | 2026-10-06 | 0001106578-26-000157 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 85 | Section 02, Martine Rothblatt 2026-10-05 | Form 4 | 2026-10-06 | 0001106578-26-000157 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 86 | Section 02, Martine Rothblatt 2026-10-05 | Form 4 | 2026-10-06 | 0001106578-26-000157 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 87 | Section 02, Martine Rothblatt 2026-10-05 | Form 4 | 2026-10-06 | 0001106578-26-000157 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 88 | Section 02, Martine Rothblatt 2026-10-05 | Form 4 | 2026-10-06 | 0001106578-26-000157 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 89 | Section 02, Martine Rothblatt 2026-10-05 | Form 4 | 2026-10-06 | 0001106578-26-000157 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 90 | Section 02, Martine Rothblatt 2026-10-05 | Form 4 | 2026-10-06 | 0001106578-26-000157 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 91 | Section 02, Martine Rothblatt 2026-10-05 | Form 4 | 2026-10-06 | 0001106578-26-000157 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 92 | Section 02, Martine Rothblatt 2026-10-05 | Form 4 | 2026-10-06 | 0001106578-26-000157 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 93 | Section 02, Martine Rothblatt 2026-10-05 | Form 4 | 2026-10-06 | 0001106578-26-000157 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 94 | Section 02, Martine Rothblatt 2026-10-05 | Form 4 | 2026-10-06 | 0001106578-26-000157 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 95 | Section 02, Martine Rothblatt 2026-10-05 | Form 4 | 2026-10-06 | 0001106578-26-000157 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 96 | Section 02, Martine Rothblatt 2026-10-05 | Form 4 | 2026-10-06 | 0001106578-26-000157 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 97 | Section 02, Martine Rothblatt 2026-10-06 | Form 4 | 2026-10-07 | 0001106578-26-000158 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 98 | Section 02, Martine Rothblatt 2026-10-06 | Form 4 | 2026-10-07 | 0001106578-26-000158 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 99 | Section 02, Martine Rothblatt 2026-10-06 | Form 4 | 2026-10-07 | 0001106578-26-000158 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 100 | Section 02, Martine Rothblatt 2026-10-06 | Form 4 | 2026-10-07 | 0001106578-26-000158 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 101 | Section 02, Martine Rothblatt 2026-10-06 | Form 4 | 2026-10-07 | 0001106578-26-000158 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 102 | Section 02, Martine Rothblatt 2026-10-06 | Form 4 | 2026-10-07 | 0001106578-26-000158 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 103 | Section 02, Martine Rothblatt 2026-10-06 | Form 4 | 2026-10-07 | 0001106578-26-000158 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 104 | Section 02, Martine Rothblatt 2026-10-06 | Form 4 | 2026-10-07 | 0001106578-26-000158 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 105 | Section 02, Martine Rothblatt 2026-10-06 | Form 4 | 2026-10-07 | 0001106578-26-000158 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 106 | Section 02, Martine Rothblatt 2026-10-06 | Form 4 | 2026-10-07 | 0001106578-26-000158 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 107 | Section 02, Martine Rothblatt 2026-10-06 | Form 4 | 2026-10-07 | 0001106578-26-000158 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 108 | Section 02, Martine Rothblatt 2026-10-06 | Form 4 | 2026-10-07 | 0001106578-26-000158 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 109 | Section 02, Martine Rothblatt 2026-10-06 | Form 4 | 2026-10-07 | 0001106578-26-000158 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 110 | Section 02, Martine Rothblatt 2026-10-06 | Form 4 | 2026-10-07 | 0001106578-26-000158 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 111 | Section 02, Martine Rothblatt 2026-10-06 | Form 4 | 2026-10-07 | 0001106578-26-000158 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 112 | Section 02, Martine Rothblatt 2026-10-06 | Form 4 | 2026-10-07 | 0001106578-26-000158 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 113 | Section 02, Martine Rothblatt 2026-10-06 | Form 4 | 2026-10-07 | 0001106578-26-000158 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 114 | Section 02, Martine Rothblatt 2026-10-06 | Form 4 | 2026-10-07 | 0001106578-26-000158 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 115 | Section 02, Martine Rothblatt 2026-10-06 | Form 4 | 2026-10-07 | 0001106578-26-000158 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 116 | Section 02, Martine Rothblatt 2026-10-07 | Form 4 | 2026-10-08 | 0001106578-26-000159 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 117 | Section 02, Martine Rothblatt 2026-10-07 | Form 4 | 2026-10-08 | 0001106578-26-000159 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 118 | Section 02, Martine Rothblatt 2026-10-07 | Form 4 | 2026-10-08 | 0001106578-26-000159 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 119 | Section 02, Martine Rothblatt 2026-10-07 | Form 4 | 2026-10-08 | 0001106578-26-000159 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 120 | Section 02, Martine Rothblatt 2026-10-07 | Form 4 | 2026-10-08 | 0001106578-26-000159 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 121 | Section 02, Martine Rothblatt 2026-10-07 | Form 4 | 2026-10-08 | 0001106578-26-000159 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 122 | Section 02, Martine Rothblatt 2026-10-07 | Form 4 | 2026-10-08 | 0001106578-26-000159 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 123 | Section 02, Martine Rothblatt 2026-10-07 | Form 4 | 2026-10-08 | 0001106578-26-000159 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 124 | Section 02, Martine Rothblatt 2026-10-07 | Form 4 | 2026-10-08 | 0001106578-26-000159 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 125 | Section 02, Martine Rothblatt 2026-10-07 | Form 4 | 2026-10-08 | 0001106578-26-000159 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 126 | Section 02, Martine Rothblatt 2026-10-07 | Form 4 | 2026-10-08 | 0001106578-26-000159 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 127 | Section 02, Martine Rothblatt 2026-10-07 | Form 4 | 2026-10-08 | 0001106578-26-000159 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 128 | Section 02, Martine Rothblatt 2026-10-07 | Form 4 | 2026-10-08 | 0001106578-26-000159 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 129 | Section 02, Martine Rothblatt 2026-10-07 | Form 4 | 2026-10-08 | 0001106578-26-000159 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 130 | Section 02, Martine Rothblatt 2026-10-07 | Form 4 | 2026-10-08 | 0001106578-26-000159 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 131 | Section 02, Martine Rothblatt 2026-10-07 | Form 4 | 2026-10-08 | 0001106578-26-000159 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 132 | Section 02, Martine Rothblatt 2026-10-08 | Form 4 | 2026-10-09 | 0001106578-26-000160 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 133 | Section 02, Martine Rothblatt 2026-10-08 | Form 4 | 2026-10-09 | 0001106578-26-000160 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 134 | Section 02, Martine Rothblatt 2026-10-08 | Form 4 | 2026-10-09 | 0001106578-26-000160 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 135 | Section 02, Martine Rothblatt 2026-10-08 | Form 4 | 2026-10-09 | 0001106578-26-000160 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 136 | Section 02, Martine Rothblatt 2026-10-08 | Form 4 | 2026-10-09 | 0001106578-26-000160 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 137 | Section 02, Martine Rothblatt 2026-10-08 | Form 4 | 2026-10-09 | 0001106578-26-000160 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 138 | Section 02, Martine Rothblatt 2026-10-08 | Form 4 | 2026-10-09 | 0001106578-26-000160 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 139 | Section 02, Martine Rothblatt 2026-10-08 | Form 4 | 2026-10-09 | 0001106578-26-000160 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 140 | Section 02, Martine Rothblatt 2026-10-08 | Form 4 | 2026-10-09 | 0001106578-26-000160 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 141 | Section 02, Martine Rothblatt 2026-10-08 | Form 4 | 2026-10-09 | 0001106578-26-000160 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 142 | Section 02, Martine Rothblatt 2026-10-08 | Form 4 | 2026-10-09 | 0001106578-26-000160 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 143 | Section 02, Martine Rothblatt 2026-10-08 | Form 4 | 2026-10-09 | 0001106578-26-000160 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 144 | Section 02, Martine Rothblatt 2026-10-08 | Form 4 | 2026-10-09 | 0001106578-26-000160 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 145 | Section 02, Martine Rothblatt 2026-10-08 | Form 4 | 2026-10-09 | 0001106578-26-000160 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 146 | Section 02, Martine Rothblatt 2026-10-08 | Form 4 | 2026-10-09 | 0001106578-26-000160 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 147 | Section 02, Martine Rothblatt 2026-10-08 | Form 4 | 2026-10-09 | 0001106578-26-000160 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 148 | Section 02, Martine Rothblatt 2026-10-08 | Form 4 | 2026-10-09 | 0001106578-26-000160 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 149 | Section 02, Martine Rothblatt 2026-10-08 | Form 4 | 2026-10-09 | 0001106578-26-000160 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 150 | Section 02, Martine Rothblatt 2026-10-09 | Form 4 | 2026-10-13 | 0001106578-26-000161 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 151 | Section 02, Martine Rothblatt 2026-10-09 | Form 4 | 2026-10-13 | 0001106578-26-000161 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 152 | Section 02, Martine Rothblatt 2026-10-09 | Form 4 | 2026-10-13 | 0001106578-26-000161 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 153 | Section 02, Martine Rothblatt 2026-10-09 | Form 4 | 2026-10-13 | 0001106578-26-000161 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 154 | Section 02, Martine Rothblatt 2026-10-09 | Form 4 | 2026-10-13 | 0001106578-26-000161 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 155 | Section 02, Martine Rothblatt 2026-10-09 | Form 4 | 2026-10-13 | 0001106578-26-000161 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 156 | Section 02, Martine Rothblatt 2026-10-09 | Form 4 | 2026-10-13 | 0001106578-26-000161 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 157 | Section 02, Martine Rothblatt 2026-10-09 | Form 4 | 2026-10-13 | 0001106578-26-000161 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 158 | Section 02, Martine Rothblatt 2026-10-09 | Form 4 | 2026-10-13 | 0001106578-26-000161 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 159 | Section 02, Martine Rothblatt 2026-10-09 | Form 4 | 2026-10-13 | 0001106578-26-000161 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 160 | Section 02, Martine Rothblatt 2026-10-09 | Form 4 | 2026-10-13 | 0001106578-26-000161 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 161 | Section 02, Martine Rothblatt 2026-10-09 | Form 4 | 2026-10-13 | 0001106578-26-000161 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 162 | Section 02, Martine Rothblatt 2026-10-09 | Form 4 | 2026-10-13 | 0001106578-26-000161 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 163 | Section 02, Martine Rothblatt 2026-10-09 | Form 4 | 2026-10-13 | 0001106578-26-000161 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 164 | Section 02, Martine Rothblatt 2026-10-09 | Form 4 | 2026-10-13 | 0001106578-26-000161 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 165 | Section 02, Martine Rothblatt 2026-10-09 | Form 4 | 2026-10-13 | 0001106578-26-000161 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 166 | Section 02, Martine Rothblatt 2026-10-09 | Form 4 | 2026-10-13 | 0001106578-26-000161 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 167 | Section 02, Martine Rothblatt 2026-10-09 | Form 4 | 2026-10-13 | 0001106578-26-000161 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 168 | Section 02, Martine Rothblatt 2026-10-09 | Form 4 | 2026-10-13 | 0001106578-26-000161 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 169 | Section 02, Martine Rothblatt 2026-10-12 | Form 4 | 2026-10-13 | 0001106578-26-000162 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 170 | Section 02, Martine Rothblatt 2026-10-12 | Form 4 | 2026-10-13 | 0001106578-26-000162 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 171 | Section 02, Martine Rothblatt 2026-10-12 | Form 4 | 2026-10-13 | 0001106578-26-000162 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 172 | Section 02, Martine Rothblatt 2026-10-12 | Form 4 | 2026-10-13 | 0001106578-26-000162 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 173 | Section 02, Martine Rothblatt 2026-10-12 | Form 4 | 2026-10-13 | 0001106578-26-000162 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 174 | Section 02, Martine Rothblatt 2026-10-12 | Form 4 | 2026-10-13 | 0001106578-26-000162 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 175 | Section 02, Martine Rothblatt 2026-10-12 | Form 4 | 2026-10-13 | 0001106578-26-000162 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 176 | Section 02, Martine Rothblatt 2026-10-12 | Form 4 | 2026-10-13 | 0001106578-26-000162 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 177 | Section 02, Martine Rothblatt 2026-10-12 | Form 4 | 2026-10-13 | 0001106578-26-000162 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 178 | Section 02, Martine Rothblatt 2026-10-13 | Form 4 | 2026-10-14 | 0001106578-26-000163 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 179 | Section 02, Martine Rothblatt 2026-10-13 | Form 4 | 2026-10-14 | 0001106578-26-000163 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 180 | Section 02, Martine Rothblatt 2026-10-13 | Form 4 | 2026-10-14 | 0001106578-26-000163 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 181 | Section 02, Martine Rothblatt 2026-10-13 | Form 4 | 2026-10-14 | 0001106578-26-000163 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 182 | Section 02, Martine Rothblatt 2026-10-13 | Form 4 | 2026-10-14 | 0001106578-26-000163 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 183 | Section 02, Martine Rothblatt 2026-10-13 | Form 4 | 2026-10-14 | 0001106578-26-000163 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 184 | Section 02, Martine Rothblatt 2026-10-13 | Form 4 | 2026-10-14 | 0001106578-26-000163 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 185 | Section 02, Martine Rothblatt 2026-10-13 | Form 4 | 2026-10-14 | 0001106578-26-000163 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 186 | Section 02, Martine Rothblatt 2026-10-13 | Form 4 | 2026-10-14 | 0001106578-26-000163 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 187 | Section 02, Martine Rothblatt 2026-10-13 | Form 4 | 2026-10-14 | 0001106578-26-000163 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 188 | Section 02, Martine Rothblatt 2026-10-13 | Form 4 | 2026-10-14 | 0001106578-26-000163 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 189 | Section 02, Martine Rothblatt 2026-10-13 | Form 4 | 2026-10-14 | 0001106578-26-000163 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 190 | Section 02, Martine Rothblatt 2026-10-14 | Form 4 | 2026-10-15 | 0001106578-26-000164 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 191 | Section 02, Martine Rothblatt 2026-10-14 | Form 4 | 2026-10-15 | 0001106578-26-000164 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 192 | Section 02, Martine Rothblatt 2026-10-14 | Form 4 | 2026-10-15 | 0001106578-26-000164 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 193 | Section 02, Martine Rothblatt 2026-10-14 | Form 4 | 2026-10-15 | 0001106578-26-000164 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 194 | Section 02, Martine Rothblatt 2026-10-14 | Form 4 | 2026-10-15 | 0001106578-26-000164 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 195 | Section 02, Martine Rothblatt 2026-10-14 | Form 4 | 2026-10-15 | 0001106578-26-000164 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 196 | Section 02, Martine Rothblatt 2026-10-14 | Form 4 | 2026-10-15 | 0001106578-26-000164 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 197 | Section 02, Martine Rothblatt 2026-10-14 | Form 4 | 2026-10-15 | 0001106578-26-000164 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 198 | Section 02, Martine Rothblatt 2026-10-14 | Form 4 | 2026-10-15 | 0001106578-26-000164 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 199 | Section 02, Martine Rothblatt 2026-10-14 | Form 4 | 2026-10-15 | 0001106578-26-000164 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 200 | Section 02, Martine Rothblatt 2026-10-14 | Form 4 | 2026-10-15 | 0001106578-26-000164 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 201 | Section 02, Martine Rothblatt 2026-10-14 | Form 4 | 2026-10-15 | 0001106578-26-000164 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 202 | Section 02, Martine Rothblatt 2026-10-14 | Form 4 | 2026-10-15 | 0001106578-26-000164 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 203 | Section 02, Martine Rothblatt 2026-10-14 | Form 4 | 2026-10-15 | 0001106578-26-000164 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 204 | Section 02, Martine Rothblatt 2026-10-14 | Form 4 | 2026-10-15 | 0001106578-26-000164 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 205 | Section 02, Martine Rothblatt 2026-10-14 | Form 4 | 2026-10-15 | 0001106578-26-000164 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 206 | Section 02, Martine Rothblatt 2026-10-14 | Form 4 | 2026-10-15 | 0001106578-26-000164 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 207 | Section 02, Martine Rothblatt 2026-10-14 | Form 4 | 2026-10-15 | 0001106578-26-000164 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 208 | Section 02, Martine Rothblatt 2026-10-15 | Form 4 | 2026-10-16 | 0001106578-26-000165 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 209 | Section 02, Martine Rothblatt 2026-10-15 | Form 4 | 2026-10-16 | 0001106578-26-000165 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 210 | Section 02, Martine Rothblatt 2026-10-15 | Form 4 | 2026-10-16 | 0001106578-26-000165 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 211 | Section 02, Martine Rothblatt 2026-10-15 | Form 4 | 2026-10-16 | 0001106578-26-000165 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 212 | Section 02, Martine Rothblatt 2026-10-15 | Form 4 | 2026-10-16 | 0001106578-26-000165 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 213 | Section 02, Martine Rothblatt 2026-10-15 | Form 4 | 2026-10-16 | 0001106578-26-000165 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 214 | Section 02, Martine Rothblatt 2026-10-15 | Form 4 | 2026-10-16 | 0001106578-26-000165 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 215 | Section 02, Martine Rothblatt 2026-10-15 | Form 4 | 2026-10-16 | 0001106578-26-000165 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 216 | Section 02, Martine Rothblatt 2026-10-15 | Form 4 | 2026-10-16 | 0001106578-26-000165 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 217 | Section 02, Martine Rothblatt 2026-10-15 | Form 4 | 2026-10-16 | 0001106578-26-000165 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 218 | Section 02, Martine Rothblatt 2026-10-15 | Form 4 | 2026-10-16 | 0001106578-26-000165 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 219 | Section 02, Martine Rothblatt 2026-10-15 | Form 4 | 2026-10-16 | 0001106578-26-000165 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 220 | Section 02, Martine Rothblatt 2026-10-15 | Form 4 | 2026-10-16 | 0001106578-26-000165 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 221 | Section 02, Paul Mahon 2026-10-15 | Form 4 | 2026-10-16 | 0001231589-26-000022 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 222 | Section 02, Paul Mahon 2026-10-15 | Form 4 | 2026-10-16 | 0001231589-26-000022 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 223 | Section 02, Paul Mahon 2026-10-15 | Form 4 | 2026-10-16 | 0001231589-26-000022 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 224 | Section 02, Paul Mahon 2026-10-15 | Form 4 | 2026-10-16 | 0001231589-26-000022 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 225 | Section 02, Paul Mahon 2026-10-15 | Form 4 | 2026-10-16 | 0001231589-26-000022 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 226 | Section 02, Paul Mahon 2026-10-15 | Form 4 | 2026-10-16 | 0001231589-26-000022 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 227 | Section 02, Paul Mahon 2026-10-15 | Form 4 | 2026-10-16 | 0001231589-26-000022 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 228 | Section 02, Paul Mahon 2026-10-15 | Form 4 | 2026-10-16 | 0001231589-26-000022 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 229 | Section 02, Martine Rothblatt 2026-10-15 | Form 4 | 2026-10-16 | 0001106578-26-000165 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 230 | Section 06, 2026 vote | Form 8-K | 2026-06-29 | 0001104659-26-078865 | Item 5.07 · say-on-pay result. As reported: 97.05% (votes for as printed: 35,152,059). Filing ↗ |
| 231 | Section 06, 2025 vote | Form 8-K | 2025-06-27 | 0001104659-25-063287 | Item 5.07 · say-on-pay result. As reported: 95.54% (votes for as printed: 38,413,776). Filing ↗ |
| 232 | Section 06, 2024 vote | Form 8-K | 2024-06-27 | 0001104659-24-075375 | Item 5.07 · say-on-pay result. As reported: 94.63% (votes for as printed: 35,662,995). Filing ↗ |
| 233 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 234 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 235 | Section 09b board cost (computed) | Computed | — | — | Cash 944,091 + equity 1,798,629 + all other 13,656 = 2,756,376, summed across the director compensation table rows.machine: formula: Σ = 2,756,376 |
| 236 | Exelixis, Section 10b CEO total | DEF 14A | 2026-04-15 | 0000939767-26-000046 | CEO total compensation as printed in Exelixis's own proxy. As printed: 33,239,183. Filing ↗machine: r2 · c10 · span 2655516–2655526 |
| 237 | Incyte, Section 10b CEO total | DEF 14A | 2026-04-28 | 0000879169-26-000031 | CEO total compensation as printed in Incyte's own proxy. As printed: 32,085,952. Filing ↗machine: t91 · r2 · c16 · span 637817–637827 |
| 238 | Gilead Sciences, Section 10b CEO total | DEF 14A | 2026-03-20 | 0001308179-26-000106 | CEO total compensation as printed in Gilead Sciences's own proxy. As printed: 28,437,198. Filing ↗machine: t414 · r1 · c29 · span 989582–989592 |
| 239 | Amgen, Section 10b CEO total | DEF 14A | 2026-04-07 | 0001193125-26-145588 | CEO total compensation as printed in Amgen's own proxy. As printed: 24,693,120. Filing ↗machine: span 1591156–1591166 |
| 240 | Biogen, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-187303 | CEO total compensation as printed in Biogen's own proxy. As printed: 23,646,004. Filing ↗machine: r2 · c16 · span 1174380–1174391 |
| 241 | PTC Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-20 | 0001104659-26-045528 | CEO total compensation as printed in PTC Therapeutics's own proxy. As printed: 23,266,326. Filing ↗ |
| 242 | Halozyme Therapeutics, Section 10b CEO total | DEF 14A | 2026-03-23 | 0001159036-26-000041 | CEO total compensation as printed in Halozyme Therapeutics's own proxy. As printed: 23,166,223. Filing ↗machine: r3 · c48 · span 478282–478292 |
| 243 | BioMarin Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-21 | 0001628280-26-026290 | CEO total compensation as printed in BioMarin Pharmaceuticals's own proxy. As printed: 21,927,563. Filing ↗machine: span 1384905–1384915 |
| 244 | Vertex Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-02 | 0000875320-26-000153 | CEO total compensation as printed in Vertex Pharmaceuticals's own proxy. As printed: 21,144,261. Filing ↗machine: r2 · c13 · span 2942799–2942809 |
| 245 | Moderna, Section 10b CEO total | DEF 14A | 2026-03-16 | 0001308179-26-000081 | CEO total compensation as printed in Moderna's own proxy. As printed: 19,932,217. Filing ↗machine: span 1132888–1132898 |
| 246 | Jazz Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-06-08 | 0001232524-26-000029 | CEO total compensation as printed in Jazz Pharmaceuticals's own proxy. As printed: 19,151,558. Filing ↗machine: r3 · c27 · span 1437369–1437379 |
| 247 | UNITED THERAPEUTICS Corp (subject), Section 10b CEO total | DEF 14A | 2026-04-29 | 0001082554-26-000009 | CEO total compensation as printed in UNITED THERAPEUTICS Corp's own proxy. As printed: 18,038,972. Filing ↗machine: span 1993726–1993736 |
| 248 | Viatris, Section 10b CEO total | DEF 14A | 2026-04-02 | 0001140361-26-013002 | CEO total compensation as printed in Viatris's own proxy. As printed: 15,273,331. Filing ↗machine: r2 · c28 · span 1344008–1344018 |
| 249 | Alnylam Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-06 | 0001628280-26-023923 | CEO total compensation as printed in Alnylam Pharmaceuticals's own proxy. As printed: 14,867,600. Filing ↗machine: span 1294691–1294701 |
| 250 | Neurocrine Biosciences, Section 10b CEO total | DEF 14A | 2026-04-15 | 0000914475-26-000015 | CEO total compensation as printed in Neurocrine Biosciences's own proxy. As printed: 13,448,935. Filing ↗machine: t50 · r4 · c7 · span 847947–847957 |
| 251 | Ionis Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-23 | 0001140361-26-016388 | CEO total compensation as printed in Ionis Pharmaceuticals's own proxy. As printed: 13,350,777. Filing ↗ |
| 252 | Pacira BioSciences, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001104659-26-050353 | CEO total compensation as printed in Pacira BioSciences's own proxy. As printed: 11,636,917. Filing ↗machine: t136 · r1 · c47 · span 2412158–2412168 |
| 253 | Illumina, Section 10b CEO total | DEF 14A | 2026-04-09 | 0001193125-26-149669 | CEO total compensation as printed in Illumina's own proxy. As printed: 11,018,895. Filing ↗machine: r4 · c14 · span 728526–728536 |
| 254 | Novavax, Section 10b CEO total | DEF 14A | 2026-04-27 | 0001628280-26-027328 | CEO total compensation as printed in Novavax's own proxy. As printed: 8,856,015. Filing ↗machine: r2 · c24 · span 944385–944394 |
| 255 | Amphastar Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-13 | 0001297184-26-000023 | CEO total compensation as printed in Amphastar Pharmaceuticals's own proxy. As printed: 8,309,350. Filing ↗machine: span 722923–722932 |
| 256 | ACADIA Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-174163 | CEO total compensation as printed in ACADIA Pharmaceuticals's own proxy. As printed: 8,256,518. Filing ↗ |
| 257 | Alkermes, Section 10b CEO total | DEF 14A | 2026-04-06 | 0001193125-26-143977 | CEO total compensation as printed in Alkermes's own proxy. As printed: 7,915,081. Filing ↗machine: r3 · c33 · span 2508258–2508267 |
| 258 | Sarepta Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177247 | CEO total compensation as printed in Sarepta Therapeutics's own proxy. As printed: 7,840,666. Filing ↗machine: span 1454395–1454404 |
| 259 | Regeneron Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-24 | 0001308179-26-000340 | CEO total compensation as printed in Regeneron Pharmaceuticals's own proxy. As printed: 7,280,549. Filing ↗machine: r3 · c10 · span 3335980–3335989 |
| 260 | Myriad Genetics, Section 10b CEO total | DEF 14A | 2026-04-14 | 0000899923-26-000031 | CEO total compensation as printed in Myriad Genetics's own proxy. As printed: 5,686,740. Filing ↗machine: r2 · c24 · span 792986–792996 |
| 261 | Section 10a, BioMarin Pharmaceuticals reciprocity | DEF 14A | — | 0001628280-26-026290 | BioMarin Pharmaceuticals names UNITED THERAPEUTICS Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 262 | Section 10a, Jazz Pharmaceuticals reciprocity | DEF 14A | — | 0001232524-26-000029 | Jazz Pharmaceuticals names UNITED THERAPEUTICS Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 263 | Section 10a, Exelixis reciprocity | DEF 14A | — | 0000939767-26-000046 | Exelixis names UNITED THERAPEUTICS Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 264 | Section 10a, Alnylam Pharmaceuticals reciprocity | DEF 14A | — | 0001628280-26-023923 | Alnylam Pharmaceuticals names UNITED THERAPEUTICS Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 265 | Section 10a, Gilead Sciences reciprocity | DEF 14A | — | 0001308179-26-000106 | Gilead Sciences's most recent proxy was read; its disclosed peer group does not include UNITED THERAPEUTICS Corp. Filing ↗ |
| 266 | Section 10a, Vertex Pharmaceuticals reciprocity | DEF 14A | — | 0000875320-26-000153 | Vertex Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include UNITED THERAPEUTICS Corp. Filing ↗ |
| 267 | Section 10a, Amgen reciprocity | DEF 14A | — | 0001193125-26-145588 | Amgen's most recent proxy was read; its disclosed peer group does not include UNITED THERAPEUTICS Corp. Filing ↗ |
| 268 | Section 10a, Amphastar Pharmaceuticals reciprocity | DEF 14A | — | 0001297184-26-000023 | Amphastar Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include UNITED THERAPEUTICS Corp. Filing ↗ |
| 269 | Section 10a, Pacira BioSciences reciprocity | DEF 14A | — | 0001104659-26-050353 | Pacira BioSciences's most recent proxy was read; its disclosed peer group does not include UNITED THERAPEUTICS Corp. Filing ↗ |
| 270 | Section 10a, PTC Therapeutics reciprocity | DEF 14A | — | 0001104659-26-045528 | PTC Therapeutics's most recent proxy was read; its disclosed peer group does not include UNITED THERAPEUTICS Corp. Filing ↗ |
| 271 | Section 10a, Novavax reciprocity | DEF 14A | — | 0001628280-26-027328 | Novavax's most recent proxy was read; its disclosed peer group does not include UNITED THERAPEUTICS Corp. Filing ↗ |
| 272 | Section 10a, Sarepta Therapeutics reciprocity | DEF 14A | — | 0001193125-26-177247 | Sarepta Therapeutics names UNITED THERAPEUTICS Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 273 | Section 10a, ACADIA Pharmaceuticals reciprocity | DEF 14A | — | 0001193125-26-174163 | ACADIA Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include UNITED THERAPEUTICS Corp. Filing ↗ |
| 274 | Section 10a, Halozyme Therapeutics reciprocity | DEF 14A | — | 0001159036-26-000041 | Halozyme Therapeutics names UNITED THERAPEUTICS Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 275 | Section 10a, Moderna reciprocity | DEF 14A | — | 0001308179-26-000081 | Moderna names UNITED THERAPEUTICS Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 276 | Section 10a, Regeneron Pharmaceuticals reciprocity | DEF 14A | — | 0001308179-26-000340 | Regeneron Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include UNITED THERAPEUTICS Corp. Filing ↗ |
| 277 | Section 10a, Neurocrine Biosciences reciprocity | DEF 14A | — | 0000914475-26-000015 | Neurocrine Biosciences names UNITED THERAPEUTICS Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 278 | Section 10a, Viatris reciprocity | DEF 14A | — | 0001140361-26-013002 | Viatris's most recent proxy was read; its disclosed peer group does not include UNITED THERAPEUTICS Corp. Filing ↗ |
| 279 | Section 10a, Ionis Pharmaceuticals reciprocity | DEF 14A | — | 0001140361-26-016388 | Ionis Pharmaceuticals names UNITED THERAPEUTICS Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.
Get the UNITED THERAPEUTICS Corp Executive Compensation Report
$1,500